Reduced Levels of Serum FGF19 and Impaired Expression of Receptors for Endocrine FGFs in Adipose Tissue From HIV-Infected Patients

Background:To determine the role of fibroblast growth factor (FGF)-19 and FGF21 and the endocrine FGFs receptor system in the metabolic alterations that manifest in HIV-1–infected patients undergoing highly active antiretroviral treatment (HAART). Methods:Serum FGF19 and FGF21 levels were determined in 4 groups of individuals as follows: (1) HIV-1–infected HAART patients with lipodystrophy (n = 38); or (2) without lipodystrophy (n = 34); (3) untreated (naive) HIV-1–infected patients (n = 34); and (4) healthy controls (n = 31). Serum FGF19 levels were correlated with anthropometric, metabolic, HIV-1 infection–related, and HAART-related parameters and with FGF21 levels. The gene expression of FGF receptor 1 and the coreceptor &bgr;-Klotho was analyzed in adipose tissue from 10 individuals from each group. Results:Serum FGF19 levels were significantly reduced in all groups of HIV-1–infected patients, whereas FGF21 levels were increased. FGF19 levels were negatively correlated with insulin resistance and insulin levels and positively correlated with high-density lipoprotein cholesterol. FGF19 was inversely correlated with cumulative exposure to nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drugs. The expression of FGF receptor 1 and coreceptor &bgr;-Klotho was reduced in adipose tissue from all groups of HIV-infected patients. Conclusions:FGF19 levels are reduced in HIV-1–infected patients, in contrast with FGF21 levels. Impaired expression of the corresponding receptor and coreceptor, which mediate the actions of endocrine FGFs in adipose tissue, suggests a resistance to the metabolic effects of FGF19 and FGF21 in HIV-1–infected patients. Considering the beneficial effects of endocrine FGFs on metabolism, the observed reduction in FGF19 levels and decreased sensitivity to endocrine FGFs in adipose tissue may contribute to metabolic alterations in HIV-1–infected patients.

[1]  F. Villarroya,et al.  Adipose tissue biology and HIV-infection. , 2011, Best practice & research. Clinical endocrinology & metabolism.

[2]  S. Kliewer,et al.  FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis , 2011, Science.

[3]  F. Villarroya,et al.  Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients , 2010, AIDS.

[4]  S. Kliewer,et al.  Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. , 2010, Molecular endocrinology.

[5]  Kathryn A. Lee,et al.  Metabolic abnormalities and coronary heart disease risk in human immunodeficiency virus-infected adults. , 2010, Metabolic syndrome and related disorders.

[6]  N. Itoh.  Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease , 2010, Cell and Tissue Research.

[7]  J. Flier,et al.  Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State , 2010, Diabetes.

[8]  M. Martínez-Chantar,et al.  Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. , 2010, Gastroenterology.

[9]  K. Brouwer,et al.  Plasma Bile Acid Concentrations in Patients with Human Immunodeficiency Virus Infection Receiving Protease Inhibitor Therapy: Possible Implications for Hepatotoxicity , 2010, Pharmacotherapy.

[10]  Yang Li,et al.  Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis , 2009, Aging.

[11]  B. Lemon,et al.  Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice , 2009, Proceedings of the National Academy of Sciences.

[12]  R. Haubrich,et al.  Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment , 2009, AIDS.

[13]  Sushant Bhatnagar,et al.  Fibroblast Growth Factor-19, a Novel Factor That Inhibits Hepatic Fatty Acid Synthesis* , 2009, Journal of Biological Chemistry.

[14]  F. Villarroya,et al.  HIV-1 Infection and the PPARγ-Dependent Control of Adipose Tissue Physiology , 2008, PPAR research.

[15]  Feng Liu,et al.  Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans , 2008, Diabetes.

[16]  Stacey A. Jones.  Mini-review: endocrine actions of fibroblast growth factor 19. , 2008, Molecular pharmaceutics.

[17]  G. Boden,et al.  Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. , 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[18]  S. Kliewer,et al.  Tissue-specific Expression of βKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21* , 2007, Journal of Biological Chemistry.

[19]  F. Mehrbod,et al.  Molecular determinants of FGF‐21 activity—synergy and cross‐talk with PPARγ signaling , 2007, Journal of cellular physiology.

[20]  T. Lundåsen,et al.  Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man , 2006, Journal of internal medicine.

[21]  F. Villarroya,et al.  HIV-1 Infection Alters Gene Expression in Adipose Tissue, Which Contributes to HIV-1/Haart-Associated Lipodystrophy , 2005, Antiviral therapy.

[22]  K. Lichtenstein.  Redefining Lipodystrophy Syndrome: Risks and Impact on Clinical Decision Making , 2005, Journal of acquired immune deficiency syndromes.

[23]  J. Gromada,et al.  FGF-21 as a novel metabolic regulator. , 2005, The Journal of clinical investigation.

[24]  I. James,et al.  Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level , 2002, Antiviral therapy.

[25]  L. Lönn,et al.  Depot-specific expression of fibroblast growth factors in human adipose tissue. , 2002, Obesity research.

[26]  C. Bouchard,et al.  A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. , 1996, The American journal of clinical nutrition.

[27]  K. Uekama,et al.  Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. , 1995, Clinical chemistry.

[28]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[29]  M. Haluzík,et al.  Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment. , 2011, Physiological research.

[30]  D. French,et al.  Printed in U.S.A. Copyright © 2002 by The Endocrine Society Transgenic Mice Expressing Human Fibroblast Growth Factor-19 Display Increased Metabolic Rate and Decreased Adiposity , 2022 .